These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 12870517)
1. Access to essential drugs. Dev World Bioeth; 2001 Nov; 1(2):89-92. PubMed ID: 12870517 [No Abstract] [Full Text] [Related]
2. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. 't Hoen E Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298 [No Abstract] [Full Text] [Related]
3. The WTO dispute settlement understanding: an unlikely weapon in the fight against AIDS. Curti AM Am J Law Med; 2001; 27(4):469-85. PubMed ID: 11837145 [No Abstract] [Full Text] [Related]
4. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity. Berger JM Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292 [No Abstract] [Full Text] [Related]
5. Essential AIDS medications in India. Thomas J Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350 [No Abstract] [Full Text] [Related]
6. TRIPS, pharmaceuticals, developing countries, and the Doha "solution". Sykes AO Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299 [No Abstract] [Full Text] [Related]
7. Access to HIV drugs: are we changing the two world paradigm? Lazzarini Z Conn J Int Law; 2002; 17(2):281-96. PubMed ID: 12688297 [No Abstract] [Full Text] [Related]
8. Ethics and AIDS drugs: some countries want to suspend patent and trade laws to get lower-cost medications to the poor. Dowell W Time; 1999 Jul; 152(4):49. PubMed ID: 11657653 [No Abstract] [Full Text] [Related]
9. Pills, patents, and power: state creation of gray markets as a limit on patent rights. Ghosh S Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138 [No Abstract] [Full Text] [Related]
10. South Africa's moral victory. Lancet; 2001 Apr; 357(9265):1303. PubMed ID: 11343727 [No Abstract] [Full Text] [Related]
11. Access to essential drugs, human rights and global justice. Shalev C Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024 [No Abstract] [Full Text] [Related]
12. Drug prices may be too high despite WTO deal. Fleck F Bull World Health Organ; 2003; 81(10):774-5. PubMed ID: 14758442 [No Abstract] [Full Text] [Related]
13. Medicines for all, not just the rich. Davey S Bull World Health Organ; 2001; 79(4):377-8. PubMed ID: 11357220 [No Abstract] [Full Text] [Related]
14. Deterring the importation of counterfeit pharmaceutical products. Stearn DW Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351 [No Abstract] [Full Text] [Related]
15. Intellectual property rights, the World Trade Organization and public health: the Brazilian perspective. Viana JM Conn J Int Law; 2002; 17(2):311-8. PubMed ID: 12688298 [No Abstract] [Full Text] [Related]
16. More drugs, less protection. Nature; 2002 Sep; 419(6904):233. PubMed ID: 12239521 [No Abstract] [Full Text] [Related]
17. The missing ingredient in medicine patent pools. Gold ER; Morin JF Lancet; 2009 Oct; 374(9698):1329-30. PubMed ID: 19837251 [No Abstract] [Full Text] [Related]
18. GATT and the gap: how to save lives. James JS AIDS Treat News; 1998 Nov; (No 307):1, 3-6. PubMed ID: 11366123 [TBL] [Abstract][Full Text] [Related]
19. International intellectual property, access to health care, and human rights: South Africa v. United States. Nagan WP Fla J Int Law; 2002; 14(2):155-91. PubMed ID: 16526137 [No Abstract] [Full Text] [Related]